Skin Cancer/Melanoma

Overall Toxicities With Immunotherapy in Melanoma
Overall Toxicities With Immunotherapy in Melanoma
BY MICHAEL A. POSTOW, MD, AND CLAIRE CROWLEY, RN
Monotherapy Versus Combination Therapy Approaches in Melanoma
Monotherapy Versus Combination Therapy Approaches in Melanoma
BY MICHAEL A. POSTOW, MD, AND MICHAEL B. ATKINS, MD
Melanoma: Speed and Durability of Therapeutic Response
Melanoma: Speed and Durability of Therapeutic Response
BY MICHAEL A. POSTOW, MD, AND MICHAEL B. ATKINS, MD
BRAF-Mutant Melanoma: Frontline Decisions
BRAF-Mutant Melanoma: Frontline Decisions
BY MICHAEL B. ATKINS, MD, AND MICHAEL A. POSTOW, MD
Immunotherapy in BRAF Wild-Type Melanoma
Immunotherapy in BRAF Wild-Type Melanoma
BY MICHAEL B. ATKINS, MD, AND MICHAEL POSTOW, MD
Initial Treatment Approach in Advanced Melanoma: Factors to Consider
Initial Treatment Approach in Advanced Melanoma: Factors to Consider
BY MICHAEL B. ATKINS, MD, AND MICHAEL POSTOW, MD
Explaining Therapeutic Options to Patients With Advanced Melanoma
Explaining Therapeutic Options to Patients With Advanced Melanoma
BY MICHAEL A. POSTOW, MD, AND MICHAEL ATKINS, MD
Multidisciplinary Care for Advanced Melanoma at Georgetown University
Multidisciplinary Care for Advanced Melanoma at Georgetown University
BY MICHAEL B. ATKINS, MD AND KELLIE GARDNER, NP
Team Approach to Advanced Melanoma Treatment at MSKCC
Team Approach to Advanced Melanoma Treatment at MSKCC
BY MICHAEL A. POSTOW, MD AND CLAIRE CROWLEY, RN
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Blogs
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2017
Intellisphere, LLC. All Rights Reserved.